In the latest quarter, 9 analysts provided ratings for Xylem XYL, showcasing a mix of bullish and bearish perspectives.
The table below provides a snapshot of their recent ratings, showcasing how sentiments have evolved over the past 30 days and comparing them to the preceding months.
| Bullish | Somewhat Bullish | Indifferent | Somewhat Bearish | Bearish | |
|---|---|---|---|---|---|
| Total Ratings | 2 | 4 | 3 | 0 | 0 |
| Last 30D | 0 | 1 | 0 | 0 | 0 |
| 1M Ago | 1 | 1 | 1 | 0 | 0 |
| 2M Ago | 1 | 0 | 0 | 0 | 0 |
| 3M Ago | 0 | 2 | 2 | 0 | 0 |
In the assessment of 12-month price targets, analysts unveil insights for Xylem, presenting an average target of $119.44, a high estimate of $140.00, and a low estimate of $101.00. This upward trend is apparent, with the current average reflecting a 3.22% increase from the previous average price target of $115.71.
Interpreting Analyst Ratings: A Closer Look
The perception of Xylem by financial experts is analyzed through recent analyst actions. The following summary presents key analysts, their recent evaluations, and adjustments to ratings and price targets.
| Analyst | Analyst Firm | Action Taken | Rating | Current Price Target | Prior Price Target |
|---|---|---|---|---|---|
| Deane Dray | RBC Capital | Raises | Outperform | $140.00 | $120.00 |
| Nathan Jones | Stifel | Raises | Buy | $136.00 | $133.00 |
| Brad Hewitt | Wolfe Research | Announces | Outperform | $127.00 | - |
| Andrew Kaplowitz | Citigroup | Raises | Neutral | $109.00 | $104.00 |
| Andy Krill | Deutsche Bank | Raises | Buy | $120.00 | $104.00 |
| Andrew Kaplowitz | Citigroup | Raises | Neutral | $104.00 | $101.00 |
| Deane Dray | RBC Capital | Lowers | Outperform | $120.00 | $123.00 |
| Bryan Blair | Oppenheimer | Announces | Outperform | $118.00 | - |
| Andrew Kaplowitz | Citigroup | Lowers | Neutral | $101.00 | $125.00 |
Key Insights:
- Action Taken: In response to dynamic market conditions and company performance, analysts update their recommendations. Whether they 'Maintain', 'Raise', or 'Lower' their stance, it signifies their reaction to recent developments related to Xylem. This insight gives a snapshot of analysts' perspectives on the current state of the company.
- Rating: Gaining insights, analysts provide qualitative assessments, ranging from 'Outperform' to 'Underperform'. These ratings reflect expectations for the relative performance of Xylem compared to the broader market.
- Price Targets: Analysts explore the dynamics of price targets, providing estimates for the future value of Xylem's stock. This examination reveals shifts in analysts' expectations over time.
Capture valuable insights into Xylem's market standing by understanding these analyst evaluations alongside pertinent financial indicators. Stay informed and make strategic decisions with our Ratings Table.
Stay up to date on Xylem analyst ratings.
About Xylem
Xylem is a global leader in water technology and offers a wide range of solutions, including the transport, treatment, testing, and efficient use of water for customers in the utility, industrial, commercial, and residential sectors. Xylem was spun off from ITT in 2011. Based in Rye Brook, New York, Xylem has a presence in over 150 countries and employs 16,200. The company generated $5.5 billion in revenue and $672 million in adjusted operating income in 2022.
Unraveling the Financial Story of Xylem
Market Capitalization Analysis: The company's market capitalization surpasses industry averages, showcasing a dominant size relative to peers and suggesting a strong market position.
Revenue Growth: Xylem displayed positive results in 3 months. As of 30 September, 2023, the company achieved a solid revenue growth rate of approximately 50.43%. This indicates a notable increase in the company's top-line earnings. As compared to its peers, the company achieved a growth rate higher than the average among peers in Industrials sector.
Net Margin: Xylem's net margin falls below industry averages, indicating challenges in achieving strong profitability. With a net margin of 7.32%, the company may face hurdles in effective cost management.
Return on Equity (ROE): Xylem's ROE lags behind industry averages, suggesting challenges in maximizing returns on equity capital. With an ROE of 1.53%, the company may face hurdles in achieving optimal financial performance.
Return on Assets (ROA): Xylem's ROA falls below industry averages, indicating challenges in efficiently utilizing assets. With an ROA of 0.95%, the company may face hurdles in generating optimal returns from its assets.
Debt Management: With a below-average debt-to-equity ratio of 0.24, Xylem adopts a prudent financial strategy, indicating a balanced approach to debt management.
The Basics of Analyst Ratings
Ratings come from analysts, or specialists within banking and financial systems that report for specific stocks or defined sectors (typically once per quarter for each stock). Analysts usually derive their information from company conference calls and meetings, financial statements, and conversations with important insiders to reach their decisions.
Some analysts also offer predictions for helpful metrics such as earnings, revenue, and growth estimates to provide further guidance as to what to do with certain tickers. It is important to keep in mind that while stock and sector analysts are specialists, they are also human and can only forecast their beliefs to traders.
This article was generated by Benzinga's automated content engine and reviewed by an editor.
© 2024 Benzinga.com. Benzinga does not provide investment advice. All rights reserved.
date | ticker | name | Price Target | Upside/Downside | Recommendation | Firm |
|---|
Trade confidently with insights and alerts from analyst ratings, free reports and breaking news that affects the stocks you care about.
